Holen Sie sich die Stockscreener-App
0.49
11.11%
0.049
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Can Outlook Therapeutics Inc. stock maintain growth trajectoryQuarterly Growth Report & Real-Time Volume Spike Alerts - mfd.ru
SPHERA FUNDS MANAGEMENT LTD. Acquires Significant Stake in Outlo - GuruFocus
Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA - TipRanks
IPO Launch: What drives Renasant Corporations stock priceQuarterly Earnings Summary & Daily Growth Stock Tips - baoquankhu1.vn
Outlook Therapeutics submits Type A meeting request to FDA following Complete Response Letter - marketscreener.com
Outlook Therapeutics Submit Type A Meeting Request To FDA Following CRL - Nasdaq
Outlook Therapeutics Submits Type A Meeting Request To FDA Following Complete Response Letter - TradingView
Outlook Therapeutics (OTLK) Faces FDA Request for Additional Evi - GuruFocus
Outlook Therapeutics seeks FDA meeting after response letter - Traders Union
FDA questions eye drug's evidence; Outlook Therapeutics seeks path forward - Stock Titan
Risk Check: Is Outlook Therapeutics Inc a top pick in the sectorEarnings Beat & Technical Confirmation Alerts - baoquankhu1.vn
Decliners Report: Can Outlook Therapeutics Inc reach all time highs this yearTrend Reversal & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
US Market Recap: Should you buy the dip on Outlook Therapeutics IncAnalyst Upgrade & Safe Entry Trade Reports - baoquankhu1.vn
Is Outlook Therapeutics Inc stock a buy or sellJuly 2025 Decliners & Intraday High Probability Setup Alerts - baoquankhu1.vn
Can Outlook Therapeutics Inc. reach all time highs this yearJuly 2025 Review & Low Risk High Reward Trade Ideas - mfd.ru
Bull Run: Will Outlook Therapeutics Inc outperform the market in YEARWeekly Market Report & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Profit Recap: Can Manhattan Associates Inc expand into new markets2025 Earnings Impact & Long-Term Investment Growth Plans - baoquankhu1.vn
Outlook Therapeutics (OTLK) price target decreased by 43.42% to 5.48 - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Outlook Therapeutics (OTLK) and Johnson & Johnson (JNJ) - The Globe and Mail
Insider Trends: Is Outlook Therapeutics Inc stock a falling knife or bargain buy2025 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
US FDA declines to approve Outlook Therapeutics' eye disease drug - AOL.com
Will Outlook Therapeutics Inc. stock outperform international peersJuly 2025 Rallies & Free Real-Time Volume Trigger Notifications - ulpravda.ru
How Outlook Therapeutics Inc. (41ON) stock trades pre earnings2025 Price Momentum & Low Drawdown Trading Strategies - ulpravda.ru
How Outlook Therapeutics Inc. stock reacts to bond yieldsEarnings Performance Report & Accurate Entry and Exit Point Alerts - ulpravda.ru
Will Outlook Therapeutics Inc. (41O) stock beat revenue estimatesJuly 2025 Recap & Accurate Technical Buy Alerts - ulpravda.ru
Published on: 2026-01-09 04:38:07 - ulpravda.ru
What catalysts could drive Outlook Therapeutics Inc. stock higher2025 Performance Recap & Stepwise Trade Signal Implementation - ulpravda.ru
Published on: 2026-01-09 02:26:13 - ulpravda.ru
Is Outlook Therapeutics Inc. (41O) stock attractive for dividend growthMarket Risk Analysis & Fast Gain Swing Alerts - ulpravda.ru
Published on: 2026-01-08 22:18:30 - Улправда
Is Outlook Therapeutics Inc. stock oversold or undervaluedM&A Rumor & Accurate Entry/Exit Alerts - ulpravda.ru
Outlook Therapeutics Appoints Laura Cantrell as VP of Corporate Strategy and Business Development - VisionMonday.com
Is Outlook Therapeutics Inc. stock vulnerable to regulatory risksStock Rotation Strategies & High Return Portfolio Growth - ulpravda.ru
Outlook Therapeutics Inc. trading halted, news pending - MSN
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know - sharewise.com
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy By Investing.com - Investing.com Nigeria
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy - Investing.com
Largest borrow rate increases among liquid names - TipRanks
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - Quiver Quantitative
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset - MSN
FDA rejects Outlook Therapeutics' third BLA submission of bevacizumab for wet AMD - Eyes On Eyecare
Outlook Therapeutics price target lowered to 50c from $1 at HC Wainwright - MSN
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright - Investing.com Canada
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright By Investing.com - Investing.com South Africa
Chardan Adjusts Price Target on Outlook Therapeutics to $1 From $3, Maintains Neutral Rating - marketscreener.com
OTLK: Chardan Capital Lowers Price Target, Maintains Neutral Rat - GuruFocus
What analysts say about Outlook Therapeutics Inc stockFlag and Pennant Patterns & Double Or Triple Wealth - earlytimes.in
Indegene Limited Included in Top Momentum ScanPortfolio Risk Assessment & Small Investment Big Gains - earlytimes.in
The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics - TipRanks
A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares - Stocktwits
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Lifecore Biomedical (LFCR) - The Globe and Mail
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):